Chapuis Lab

Chapuis Lab

Group photo of the Chapuis Lab

Our Research

Dr. Aude Chapuis is an expert in hematopoietic stem cell transplantation and in developing novel ways to help a patient’s immune system target life-threatening viral infections and various malignancies. Building on positive results with adoptive transfer of T cells targeting specific antigens in HIV and melanoma, her Program in Immunology laboratory is focused on understanding the factors associated with successful therapies so that adoptive T cells therapies can be further optimized to better eliminate tumors.

With particular expertise in obtaining and validating T cell receptors (TCRs) that bind specific target antigens, generating antigen-specific T cells and preparing certified T cell products for patients, ongoing studies in the Chapuis lab aim to 1) improve the survival and intrinsic antitumor activity of adoptively transferred T cells and 2) modulate the immune “microenvironment” in the patient to improve therapeutic T cell activity. Clinical trials and correlative laboratory studies are underway for patients with myeloid leukemia, lung cancer and Merkel cell carcinoma.
 

Featured Publications

Nature Medicine 2019

Chapuis AG, Egan DN, Schmitt TM, McAfee MS, Paulson KG, Voillet V, Gorttardo R, Ragnarsson GB, Bleakley M, Yeung CC, Mulhauser P, Nguyen HN, Kropp LA, Castelli L, Wagener F, Hunter D, Lindberg M, Cohen K, Seese A, McElrath J, Duerkopp N, Gooley TA, Greenberg PD. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.

 

Nature Communications 2018

Paulson KG, Voillet V, McAfee MS, Hunter DS, Wagener FD, Perdicchio M, Valente WJ, Koelle SJ, Church CD, Vandeven N, Thomas H, Colunga AG, Iyer JG, Yee C, Kulikauskas R, Koelle DM, Pierce RH, Bielas JH, Greenberg PD, Bhatia S, Gottardo R, Nghiem P, Chapuis AG. Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA.

Science Immunology 2017

Chapuis AG, Desmarais C, Emerson R, Schmitt TM, Shibuya K, Lai I, Wagener F, Chou J, Roberts IM, Coffey DG, Warren E, Robbins H, Greenberg PD, Yee C. Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8+ T Cells In Vivo.

About the Program in Immunology

Investigators in The Program in Immunology are learning how immune cells respond to disease and how to safely enhance immune responses to better control, cure and potentially prevent cancers and other serious diseases. Nobel Prize-winning work on bone marrow transplantation began in the 1960s at the Fred Hutch, and provided the first definitive example of the immune system’s curative power. Fred Hutch researchers went on to show that donor immune T cells play a major role in successful transplant outcomes. In the 1990s, Program in Immunology investigators proved that antigen-specific T cells can be isolated, expanded in the laboratory and adoptively transferred to patients to augment T cell immunity. Techniques have since been developed to genetically engineer T cells to enhance their survival and their anti-cancer activities. And, studies are now showing how to use other types of immune cells to boost therapeutic immune responses. With our depth and breadth of expertise, we are advancing a detailed understanding of immunological processes and developing revolutionary immunotherapies to fight disease.